Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression.
Cellestia's investors include Partners Investment, Innosuisse, GoBeyond, Foundation for Innovation and Technology (FIT), EISMEA.
Cellestia is headquartered in Basel, Switzerland.
Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression.
Cellestia is at the Non-equity Assistance stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cellestia — Funding & Investors." VCBacked, June 27, 2023, https://www.vcbacked.co/company/cellestia. Accessed September 30, 2026.
VCBacked. (2023). Cellestia — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/cellestia
{{cite web |title=Cellestia — Funding & Investors |url=https://www.vcbacked.co/company/cellestia |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated